Nowoczesne metody diagnostyki kardiotoksycznosci antracyklin u pacjentow z chloniakami

Abstract

Author(s): Beata Kumiega, Andrzej Pluta, Jacek Krzanowski

Anthracyclines, show a strong antitumour activity in the treatment of solid and haematological malignancies. They may be responsible for cardiac side effects. Initially, cardiac damage induced by anthracyclines is subclinical, however increasingly impaired cardiac function can result chronic heart failure. The assessment of the myocardial damage, especially at its initial stage is very important however difficult. There is a continuous need for new methods introduction of early detection of cardiac damage.

Share this article

Editors List

  • S.SREEDHAR

    Submitted PhD thesis in Biotechnology at GITAM University, Vizag.

  • Yousef Alomi

    Yousef Alomi
    The Past Head, General Administration of Pharmaceutical Care at Ministry of Health,
    Saudi Arabia Critical Care/TPN
    Clinical Pharmacist Ministry of Health,
    Riyadh, Saudi Arabia.

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

Google Scholar citation report
Citations : 61

Onkologia i Radioterapia received 61 citations as per Google Scholar report

Onkologia i Radioterapia peer review process verified at publons
Indexed In
  • Scimago
  • SCOPUS
  • MIAR
  • Euro Pub
  • Google Scholar
  • Medical Project Poland
  • PUBMED
  • Cancer Index
  • Gdansk University of Technology, Ministry Points 20